Figure 7

Amiodarone inhibits GBM tumor xenograft growth. Amiodarone’s anti-tumor activity following systemic administration (I.P.) evaluated in a S.C. tumor model. Foxn1 nu mice were inoculated S.C. with 5 × 106 U-87 MG cells. When tumors reached an average volume of ~ 200 mm³, mice were divided into two groups of treated (Amiodarone 0.1 mg/kg I.P. injection q.d.) and untreated (given saline) mice over a course of 14 days. (A, B) Tumors were surgically resected and collected when an average volume of ~ 1000 mm³ (day 14) was reached. (C, D) Weight and volume of tumors from treated and untreated mice were measured. Tumor volume was calculated using the standard equation (length × width² × 0.52). n = 3–5. *p < 0.05, **p < 0.01, compared with non-treated control mice. Results are presented as mean ± SEM. (E) Representative histologic sections of untreated tumor (left) and Amiodarone-treated tumor (right) of mice post-H&E staining. Scale bar: 100 µm. (F) Representative images of tumor sections stained with anti-CD31 (DAB-brown) and Gill’s Hematoxylin for nuclei staining (blue). Untreated tumor (top) and Amiodarone-treated tumor (bottom). Scale bar: 100 µm. Objective lens 10 × . The data of harvesting livers, spleens and lungs of control mice and Amiodarone-treated mice on day 14 are not shown here but are discussed in the Results section and in Fig. 7–figure supplement 1. The data of Amiodarone 0.05 mg/kg I.P. injection q.d. treatments are discussed in the Results section and shown in Fig. 7–figure supplement 2. Figure supplement 1. Effect of Amiodarone in GBM tumor xenograft. Figure supplement 2. Amiodarone reduces GBM tumor xenograft volume.